Remove 2024 Remove FDA Remove Pharma Remove Side effects
article thumbnail

Think Tank – Building Trust Equity

PM360

We must prioritize open and honest communication that satisfies the audience’s need for understandable information while simultaneously sticking to FDA guidelines. It’s tough, but pharma brands should make sure their messaging is consistent, whether it is aired on traditional linear TV, OTT media, or CTV. So, how do we fix this?

Ethics 59
article thumbnail

Immutep’s LAG-3 drug ‘dramatically undervalued,’ says analyst

pharmaphorum

Immutep claimed fast-track status from the FDA for efti last week as a combination therapy alongside Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) for previously-untreated non-small cell lung cancer (NSCLC), based on the results of the phase 2 TACTI-002 study. month mPFS with Keytruda plus chemo, with fewer side effects.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape

Pharmaceutical Representative Training

Pharmaceutical representatives (pharma reps) are facing new challenges as a result of these transformations that have drastically altered the pharmaceutical sales landscape. Essential Competencies in Pharmaceutical Sales First, let’s review the competencies of a successful sales rep in pharma.

Sales 52
article thumbnail

From Lab to Patient

PM360

By identifying biological targets for new drugs and finding potential compounds that interact effectively with the target, new compounds can be developed that enhance effectiveness and reduce side effects. This analysis can inform trial designers about the necessary adjustments to make trials more inclusive.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market.

article thumbnail

Aiming for ‘Magic Bullets’ in Medicine: Are We Shooting Ourselves in the Foot?

Clarivate

A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious side effects. [2] 6] As many pathogenetic targets have multiple physiological functions, highly specific ‘magic bullets’ may impact multiple cellular pathways simultaneously, causing unintended side effects.7

article thumbnail

ICER says new ALS drugs offer ‘low’ value for money

pharmaphorum

It has, however, been cleared by Health Canada under the Albrioza brand name, and the FDA is due to decide on the US marketing application later this month. ” AMX0035 (phenylbutyrate/ursodoxicoltaurine), meanwhile, isn’t yet approved in the US, so its price there hasn’t been set.